Host Cell Protein Testing Patents: Top Companies & Trends 2026
Host Cell Protein and Residual Testing Patents
57.2% of all 593 records sit with just five assignees, and 77.2% with ten — this is a field with a narrow, well-defended core rather than a wide-open one. Filings climbed to a peak of 50 in 2018, then eased through the early 2020s. The clearest complete-year comparison the data supports is 2021 to 2024: filings fell from 48 to 25, a 48% decline over that span. Figures for 2025 and 2026 are still filling in and should not be read as a continuation of that decline.
- 1AMGEN INC120
- 2SCIENTIST OF FORTUNE62
- 3BRISTOL MYERS SQUIBB CO62
- 4GLOBAL BIOENERGIES62
- 5NOVARTIS AG33
See the full host cell protein and residual testing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in host cell protein and residual DNA testing?
One assignee leads the field with 120 records, well ahead of the fifth-place holder at 33. The top five assignees combined account for 57.2% of all 593 records in scope, and the top ten account for 77.2%, so filing activity in this space is concentrated among a small number of large biologics manufacturers rather than spread evenly across the field. A freedom-to-operate review should prioritise those leading names before looking further down the ranking.
Is patent filing in HCP testing growing or slowing?
Filings peaked at 50 in 2018 and, over the most recent complete comparison available, fell from 48 in 2021 to 25 in 2024 — a 48% decline. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as continuing that decline; they simply have not caught up yet. The honest read is that filing activity has cooled from its 2018 peak, not that the technology has stopped moving.
What technology areas dominate host cell protein patent claims?
Claims cluster heavily in C07K (peptides & proteins, 46.2% of records), C12P (fermentation & enzymatic synthesis, 42.7%) and C12N (microorganisms & genetic engineering, 39.1%). Classes tied directly to the assay method itself — G01N for material analysis and testing, and C12Q for enzyme- or DNA-based measuring — cover only 11.3% and 7.1% of records respectively. That split means most protection in this field sits around the biologic and how it is produced, not around the detection technique used to test it.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Host Cell Protein and Residual Testing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.